Stock Upgrades Today

 TopRated
 
  TopRated
 
Follow  Message
 
 
 
TopRatedStocks uncovering top-rated companies. Providing quick insights and recommendations, they help investors discover high-potential stocks based on robust metrics.
 

•  07 Jan 2026
 

•   ACN  
   
  +2.84%
•   ALB  
   
  -0.10%
•   ALLO  
   
  +12.50%
•   ALLY  
   
  -1.72%
•   AMZN  
   
  +2.11%

$ACN Accenture picked up a Buy initiation from Truist Securities, a vote of confidence in the firm ability to keep monetizing digital transformation, cloud migration, and AI-driven consulting. The implied upside is modest at around mid-single digits, but for traders, this upgrade reinforces ACN role as a steady compounder rather than a momentum name.

$ALB Albemarle saw a decisive tone shift as Baird upgraded the stock to Outperform and nearly doubled its price target. The call reflects renewed optimism around lithium pricing normalization and long-term EV demand. After a bruising cycle, traders are watching closely to see if this marks the start of a durable sentiment reversal.

$ALLO Allogene received a Buy initiation from UBS with an $8 target, signaling cautious optimism around its pipeline and balance sheet reset. While still speculative, the coverage suggests downside risk may be better defined, which can matter for biotech traders hunting asymmetric setups.

$ALLY Ally Financial was upgraded to Outperform by Evercore ISI, with analysts pointing to improving credit trends and operating leverage. The projected upside is not dramatic, but the upgrade adds credibility to the idea that regional and consumer-focused financials may be stabilizing.

$AMZN Amazon continues to attract bullish commentary, with Jefferies raising its price target to $300 and reiterating Buy. The focus remains on margin expansion in AWS and advertising, keeping AMZN firmly in the leadership camp for large-cap growth traders.

$APGE Apogee Therapeutics entered coverage at UBS with a Buy rating and a $100 target. The initiation underscores confidence in its differentiated immunology assets, making APGE a name that could see volatility as milestones approach.

$APLD Applied Digital drew a Buy initiation from H.C. Wainwright with a $25 target, highlighting optimism around its data center and high-performance computing exposure. For traders, this is a classic higher-risk, higher-reward infrastructure play tied to AI demand.

$ARVN Arvinas was upgraded to Buy by Citigroup, with double-digit upside implied. The upgrade reflects growing confidence in its protein degradation platform, which has started to regain credibility after a volatile stretch.

$ASML ASML saw one of the most dramatic tone shifts, with an analyst flipping from Sell to Buy and doubling the price target to $1500. The call hinges on surging EUV demand and renewed confidence in the semiconductor cycle, making ASML a core AI and chips bellwether again.

$BIDU Baidu benefited from a higher price target at Jefferies following its AI chip unit spin-off plans. Analysts see potential value unlock, and for traders, BIDU represents a China AI name with improving narrative clarity.

$BKD Brookdale Senior Living was upgraded to Buy by BofA despite limited near-term upside. The move suggests downside risk may be largely priced in, appealing more to longer-term recovery investors than short-term traders.

$CERT Certara stood out with a sizable upgrade-driven upside estimate after Leerink moved the stock to Outperform. Strength in regulatory science software and services positions CERT as a quieter but compelling healthcare tech story.

$CMC Commercial Metals earned a Buy upgrade from Jefferies ahead of earnings, with analysts citing improving fundamentals and shareholder returns. The stock appeals to traders looking for industrial exposure with income support.

$COF Capital One has enjoyed multiple upgrades as litigation uncertainty clears. The improved visibility has shifted focus back to earnings power and balance sheet strength, which could re-rate the stock higher.

$CWST Casella Waste Systems was upgraded to Buy by Jefferies, reflecting confidence in pricing power and steady cash flows. It is not flashy, but defensive names like CWST often attract capital during rotation phases.

$CYD China Yuchai received a Buy initiation from UBS, though the implied upside is limited. The call is more about valuation support than a near-term catalyst.

$DUOL Duolingo grabbed attention with a Buy initiation from Truist and an eye-catching 70% upside forecast. The upgrade highlights strong user growth and monetization, positioning DUOL as one of the more compelling consumer-tech momentum stories.

$FTRE Fortrea was upgraded to Outperform by Evercore, even as analysts still see downside. This mixed signal suggests the market may be underestimating operational improvements, but conviction remains cautious.

$HLF Herbalife was initiated at Buy by Maxim, though analysts still model downside. Traders will likely treat this as a tactical sentiment call rather than a fundamentals-driven shift.

$IBM IBM earned a Buy upgrade from Jefferies on expectations of software acceleration driven by Red Hat and hybrid cloud momentum. The call reinforces IBM’s gradual transformation narrative, appealing to value-oriented tech traders.

$LMND Lemonade received a Buy initiation from Truist despite projected downside, underscoring belief in its long-term model but skepticism about near-term execution.

$MBLY Mobileye was upgraded to Neutral by JPMorgan, with analysts flagging substantial upside potential. The shift suggests downside risk may be limited after underperformance, keeping MBLY on traders’ rebound watchlists.

$MCD McDonald’s drew renewed optimism from Oppenheimer, which sees meaningful upside after a prolonged period of stagnation. The upgrade leans on operational resilience and global brand strength.

$MDT Medtronic was upgraded to Outperform by William Blair, pointing to improving fundamentals and pipeline execution. It is a steady healthcare name that could regain favor as risk appetite balances out.

$META Meta-related commentary remained constructive, with analysts reiterating Buy ratings tied to AI-driven efficiency and earnings leverage, keeping META firmly in the leadership narrative.

$NVS Novartis was upgraded to Equal-Weight by Barclays, a more neutral shift that suggests risk is better balanced after prior underperformance.

$NWL Newell Brands continues to see mixed views, but reiterated Buy ratings highlight turnaround potential. Traders remain divided on timing versus patience.

$OI O-I Glass was upgraded to Overweight by Wells Fargo, citing improving outlook and manageable upside. The move adds support to the industrial recovery theme.

$PANW Palo Alto Networks was upgraded to Neutral by Guggenheim, with analysts noting improved risk-reward after underperformance and solid cash flow leadership. It is a reset call rather than an outright bullish bet.

$TFC Truist Financial was upgraded to Outperform by Evercore, reflecting stabilization in regional banking fundamentals and modest upside expectations.

$VRDN Viridian Therapeutics received a Buy initiation from UBS tied to its TED treatment, placing it firmly in the speculative biotech category with catalyst-driven potential.

$VRT Vertiv was upgraded to Overweight by Barclays, with a raised $200 target. Analysts are leaning into AI infrastructure demand, making VRT one of the clearer beneficiaries of data center expansion.

$VTYX Ventyx Biosciences was initiated at Buy by UBS with a $20 target, signaling optimism around its clinical pipeline despite inherent biotech risk.

$WRBY Warby Parker surged following a price target hike, with optimism around AI-enabled glasses and brand momentum. The move highlights how narrative shifts can drive sharp near-term price action.

$XPEV XPeng was upgraded to Buy by Freedom Capital, with analysts pointing to significant upside. For traders, it represents a higher-beta EV play tied to China sentiment.

$ZLAB Zai Lab entered coverage at UBS with a Buy rating and a $35 target, reflecting confidence in its oncology portfolio and regional growth strategy.

View All Headlines